|
The Derwent Drug File presents information on all aspects of drug
research and usage.
DDFU selectively covers the worldwide pharmaceutical literature,
papers chosen may cover the chemistry, analysis, pharmaceutics,
pharmacology, metabolism, biochemistry, interactions, therapeutic
effects and toxicity of a drug.
Each document in DDFU contains a detailed abstract written by a
Derwent subject specialist and is accompanied by extensive drug
oriented indexing allowing highly specific retrieval. The Derwent
Drug File will be of particular interest to information specialists
and research scientists working in the pharmaceuticals and health
care industries. DDFU is open to subscribers only. DDNS contains
everything but the extension abstract and is available to all.
Use DDFU/DDNS to research:
- the use of ondansetron to treat cisplatin-induced vomiting.
- the compatibility of ranitidine with antacid preparations.
- structure-activity relationships of pyrimidine nucleoside
anti-HIV agents.
- the use of targeted drug delivery systems for anticancer agents.
- pharmacokinetics of drugs used to treat psoriasis.
Sources:
Papers from over 1,150 scientific and medical journals and
conference proceedings are included. A full list of titles covered
is available from the producer.
Accession number & update
1993-22688 930601.
Occurrences
PARAGRAPH
AN (1)
Title
Antihypertensive Effects of YM358, a Novel Angiotensin II
Receptor Antagonist.
Author(s)
Shibasaki-M, Fujimori-A, Yatsu-Y, Matsuda-Y, Inagaki-O, Okazaki-
T.
Source
Jpn-J-Pharmacol (61, Suppl. 1, 212P, 1993) Coden: JJPAAZ.
Publication year
93.
Company name
Yamanouchi.
Location
Ibaraki, Jap.
Language
EN.
Thematic groups
Pharmacology (P).
Section
58 Vasoactive; 72 New Drugs; 73 Trial Preparations.
Abstract (A1 A2)
The antihypertensive effects of p.o. YM-358 (2,7-diethyl 5-((2'-
(5-tetrazolyl)biphenyl 4-yl)methyl)-5H-pyrazolo (1,5-b)(1,2,4)
triazole potassium salt) were evaluated in conscious rats and
dogs and compared with those of DUP-753. In renal hypertensive
rats (RHR), YM-358 had a sustained antihypertensive effect with a
rapid onset of action, and it lowered mean B.P. (MBP) in
normotensive rats (NTR) and SHR. In contrast, DUP-753 produced an
antihypertensive effect that was extremely slow in onset and long
in duration in SHR and RHR. The antihypertensive activity of
DUP-753 in furosemide-treated dogs (FTD) was modest compared to
YM-358. The results demonstrate that YM-358 is a novel, long-
acting antihypertensive agent in the rat and dog. (congress
abstract).
In 2 kidneys, 1 clip renal RHR (high-renin hypertensive model), a
single p.o. administration of YM-358 (1-30 mg/kg) produced a
dose-dependent reduction in MBP without affecting HR. The
hypotensive effect of YM-358 reached a maximum about 1 hr after
dosing and lasted over 10 hr. Similarly, YM-358 lowered MBP in
NTR and SHR. In contrast, p.o. 3-30 mg/kg DUP-753 produced an
antihypertensive effect that was extremely slow in onset and long
in duration in SHR and RHR. The rank orders of hypotensive
activities of YM-358 and DUP-753 were RHR greater than SHR
greater than NTR. On the other hand, in FTD (high-renin
normotensive model), a single p.o. administration of YM-358 (10
and 30 mg/kg) dose-dependently decreased MBP without affecting
HR. Its duration of action exceeded 8 hr. The antihypertensive
activity of p.o. 10 and 30 mg/kg DUP-753 in FTD was modest
compared to YM-358. (JC)
Central Research Laboratories, Yamanouchi Pharmaceutical Co.,
Ltd., Tsukuba, Ibaraki 305, Japan. (8 authors).
Common terms
SPONTANEOUS/OC; HYPERTENSION/OC; VASCULAR-DISEASE/OC; RENAL/OC;
FUROSEMIDE/RC; IN-VIVO/FT; DOG/FT; RAT/FT; P-O/FT; DRUG-
COMPARISON/FT; HYPOTENSIVE/FT; BLOOD-PRESSURE/FT; HEART-RATE/FT;
LAB-ANIMAL/FT; HEMODYNAMICS/FT.
Link terms
1 OF 2.
*01* YM-358/PH; TRIAL-PREP/FT; HYPOTENSIVES/FT; ANGIOTENSIN-
ANTAGONISTS/FT; NEW/FT; PYRAZOLE/FT; COND-RING/FT; TRIAZOLE/FT;
TRIAZENE/FT; ARALKYLAMINE/FT; BIPHENYL/FT; BB-LINKED/FT; BH-
LINKED-CC/FT; TETRAZOLE/FT; PH/FT; 02A/G3; 02H/G3; 022/G3; 03A
/G3; 033/G3; 06A/G3; 06H/G3; 066/G3; 067/G3; 07A/G3; 07H/G3; 074
/G3; 08A/G3; 08H/G3; 082/G3; 085/G3; 087/G3; 088/G3; 094/G3; 096
/G3; 10H/G3; 100/G3; 103/G3; 105/G3; 106/G3; 11A/G3; 11H/G3; 115
/G3; 125/G3; 134/G3; 163/G3; YM-358/RN.
2 OF 2.
*02* DUP-753/PH; TRIAL-PREP/FT; ANGIOTENSIN-ANTAGONISTS/FT;
DUP-753/RN; PH/FT.
Labels/description Example
AN Accession number 1_: 93-22688.AN.
& update - see Limit options -
OC Occurrences - Display only -
TI Title 2_: ANTIHYPERTENSIVE WITH
ANGIOTENSIN.TI.
AU Author(s) 3_: FUJIMORI-A$
CO Company name 4_: YAMANOUCHI.CO.
LO Location 5_: IBARAKI.LO.
IN Author affiliation 6_: TSUKUBA.IN.
SO Source 7_: JPN-J-PHARMACOL
YR Publication year 8_: YEAR=1993
LG Language 9_: EN.LG.
TG Thematic groups 10_: PHARMACOLOGY.TG.
SC Section 11_: HYPOTENSIVES.SC.
or 12_: 58.SC.
AB Abstract (A1 A2) 13_: YM ADJ 358 WITH
ANTIHYPERTENSIVE
A1 Abstract summary 14_: FUROSEMIDE
A2 Abstract extension 15_: HYPERTENSIVE ADJ MODEL.A2.
DE Descriptors (CT LT) 16_: FUROSEMIDE-RC
CT Common terms 17_: RENAL WITH OC.DE.
LT Link terms 18_: ANGIOTENSIN-ANTAGONISTS.LT.
19_: 31828-71-4
NT Notes 20_: FIG.NT.
AY= Accession year 1_: AY=1993
YEAR= Publication year 2_: YEAR=1992
LG= Language 3_: LG=EN
TG= Thematic Groups 4_: TG=C
SC= Sections 5_: SC=58
1_: HYPOTENSIVES.DE.
YEAR Publication Year YY 2_: ..L 1 YEAR EQ 1992
UDATE Update date YYYYMMDD 3_: ..L 1 UDATE<19931001
UMONTH Update month YYYYMM 4_: ..L 1 UMONTH WL 199307,199312
AY Accession year YYYY 5_: ..L AY>1992
In the DE paragraph
Animal (A) Y/N 6_: ..L 1 ANIMAL=Y
Human (H) Y/N 7_: ..L 1 H=Y.
By paragraph - author, title: _: ..P AU, TI 1-20
SHORT AN OC TI AU SO
MEDIUM AN OC TI AU SO CO LO IN A1
LONG AN OC TI AU SO CO LO AB (A1 A2*) DE (CT LT)
ALL AN OC TI AU SO YR CO LO IN LG TG SC AB (A1 A2 *)
DE (CT LT)
HITS All paragraphs where search terms occur
FREE AN OC TI YR LG DE (CT LT)
_: ..P LONG 5,7-10
* A2 paragraph available in DDFU only.
DE/CT/LT - Descriptors:
A standard name (e.g. INN, USAN, laboratory code) is used to
identify each drug. In addition the pharmacological classification
and the drug activity are also indexed
There are two types of descriptor - Common Terms in the CT field
and Link Terms in the LT field. For most descriptor searches it
is best to qualify to the superlabel DE.
Common Terms (CT) - this contains all those terms that are common to
the whole document. CT may be present in any document where more
than one drug is discussed in the original article. If you know that
the descriptors you are searching are Common Terms then qualify to
CT, otherwise always use DE.
Link Terms (LT) - these are divided into separate indexing fields;
each field containing all the descriptors related to a single drug.
If you know that the descriptors you are searching are Link Terms
then qualify to LT, otherwise always use DE to include any
descriptors that are listed in the Common Terms field.
Always use the SAME operator to link different terms - eg:
CHLOROPROMAZINE SAME PHARMACOKINETICS.DE.
You can use the WITH operator of hyphens to link a descriptor term
to the appropriate drug/disease qualifiers - e.g.:
PARACETAMOL WITH PH.DE.
or:
PARACETAMOL-PH (paragraph qualification not necessary)
This will retrieve documents relating to the pharmacology of
paracetamol.
Drug and Disease Qualifiers:
AE Side effect; toxicity
DI Drug interaction (used for drugs only)
DM Drug metabolism (used for drugs only)
FT Further term
G1-G8 General chemical codes
OC Other context
PH Pharmacology (used for drugs only)
PI Inorganic code/ Physical code
PP Peptide code
RC Reference compound (used for drugs only)
RN Registry name
SS Steroid code
TR Treatment
Search Options:
..SET PLURALS ON and ..SET MEDWORD ON can be selected in DDFU/DDNS
Do not use ..SET PLURALS ON when searching for a specific drug
activity or class.
Guides:
The guide to DDFU is published in the Biomedical Manual, Berne and
online in the BASE database - search BASE-DDFU.
Back to the Datasheet Index Page
© 2008 Dialog DataStar
|